Concretely: early satiety · tirzepatide · SURMOUNT-2.
The figures are clear enough; the question is what they mean and what they do not.
I can supply the numbers if the specifics change the answer.
How should I read this, and where are the traps?
Take it from the SURMOUNT-2 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.
Stated carefully, diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.
The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.
It helps to be literal here: anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Symptoms appearing late at a stable dose deserve a differential diagnosis rather than an assumption.
Smaller meals, less fat, fluids between rather than with. In that order.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThis is the group of effects that drives almost all discontinuation in the trial programmes.
Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.
Research-use compounds are not approved for human use.
New symptoms at a stable dose after months need a different explanation.
The honest answer is that the first eight weeks are the hard part and that most people who get through them stop having the conversation.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
It helps to be literal here: symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Four-weekly titration intervals in the licensed schedules were selected to allow tolerance between escalations.
Most people who report these effects continue. The discontinuation rate is low.
Reflux is the symptom people least expect and it follows directly from a stomach that empties slowly.
Reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.
Dietary fat slowing gastric emptying is basic gastrointestinal physiology and independent of any drug effect.
Nothing here is medical advice.
Everything except constipation attenuates. Plan differently for that one.
edited 15 Aug 2024 by sunniva_dahl — added the method parameters
Answering this needs the titration history, because going faster than the schedule is the single largest modifiable factor.
Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.
The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.
The caveat is that severe persistent symptoms, particularly with dehydration or severe pain, are clinical and not a matter of waiting them out.
Slow the titration first. It is the intervention with the best evidence and the lowest cost.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.